Ignite Creation Date:
2024-05-05 @ 4:37 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00281515
Status:
COMPLETED
Last Update Posted:
2012-06-29
First Post:
2006-01-24
Brief Title:
Comparison of PaclitaxelCarboplatin and Lonafarnib to PaclitaxelCarboplatin for First-line Treatment of Ovarian Cancer
Sponsor:
AGO Study Group
Organization:
AGO Study Group
Study Overview
Official Title:
An Open-label Multicenter Randomized Phase II Study to Compare the Effects of PaclitaxelCarboplatin and Lonafarnib to Those of PaclitaxelCarboplatin for First-line Treatment of Patients With Epithelial Ovarian Cancer FIGO Stages IIB-IV
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the effects of PaclitaxelCarboplatin and Lonafarnib to those of PaclitaxelCarboplatin in primary treatment of patients with epithelial ovarian cancer
Detailed Description:
Today the standard therapy for patients with advanced ovarian carcinoma is paclitaxel and carboplatin Lonafarnib is a farnesyl transferase inhibitor FTI that is active against a broad spectrum of tumor cell lines in vitro and tumor xenografts in nude mice Lonafarnib has single-agent antitumor activity as well as enhanced activity in combination with taxanes in a number of tumor cell lines and in vivo models
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None